New Ray Medicine International Holding Limited provided earnings results guidance for the six months ended 30 June 2018. For the period, the company is expected to record a loss on equity instruments at fair value through other comprehensive income on listed securities in Hong Kong of approximately HKD 2.5 million for the six months ended 30 June 2018 ("2018 Interim Period"), as compared to an unaudited loss of approximately HKD 65.4 million for the six months ended 30 June 2017. As at 30 June 2018, certain of the Group's equity instruments at fair value through other comprehensive income comprised listed securities in Hong Kong, the trading of which had been suspended as directed by the Securities and Futures Commission. The Company has engaged an independent professional value to assess the value of such suspended securities as at 30 June 2018.